EcoDrugPlus

Tyrosine-Protein Kinase Jak2-Like

Ensembl ID : ENSCSEG00000016532
Gene Symbol: LOC103397589
3 Cross references
194 Possible Orthologues:

Tyrosine-Protein Kinase Fyna

Ensembl ID : ENSCSEG00000003064
Gene Symbol: LOC103378673
3 Cross references
192 Possible Orthologues:

Tyrosine-Protein Kinase Yes

Ensembl ID : ENSCSEG00000013873
Gene Symbol: LOC103396430
3 Cross references
197 Possible Orthologues:

Uncharacterized Loc103383236

Ensembl ID : ENSCSEG00000020832
Gene Symbol: LOC103383236
2 Cross references
192 Possible Orthologues:

Uncharacterized Loc103393310

Ensembl ID : ENSCSEG00000006306
Gene Symbol: LOC103393310
2 Cross references
194 Possible Orthologues:

Uncharacterized Loc103393819

Ensembl ID : ENSCSEG00000016812
Gene Symbol: LOC103393819
2 Cross references
215 Possible Orthologues:

Urotensin 2 Receptor

Ensembl ID : ENSCSEG00000020321
Gene Symbol: UTS2R
3 Cross references
92 Possible Orthologues:

Vascular Endothelial Growth Factor A

Ensembl ID : ENSCSEG00000019656
Gene Symbol: VEGFA
3 Cross references
197 Possible Orthologues:

Vascular Endothelial Growth Factor A-A-Like

Ensembl ID : ENSCSEG00000010702
Gene Symbol: LOC103388751
3 Cross references
180 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSCSEG00000003582
Gene Symbol: VDR
3 Cross references
392 Possible Orthologues:

Vitamin D3 Receptor B

Ensembl ID : ENSCSEG00000004882
Gene Symbol: LOC103386109
3 Cross references
394 Possible Orthologues:

Vitamin K Epoxide Reductase Complex Subunit 1-Like Protein 1

Ensembl ID : ENSCSEG00000019605
Gene Symbol: LOC103382040
3 Cross references
191 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).